📰 Nasdaq Frln News
Nasdaq Frln News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Frln. Real-time updates on events, politics, business and more.
January 2, 2024
Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 51,400 shares, a drop of 35.3% from the November 30th total of 79,500 shares. Based on an average daily volume of 220,800 shares, the days-to-cover […]
January 2, 2024
Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Get Free Report) was the target of a large decline in short interest in December. As of December 15th, there was short interest totalling 51,400 shares, a decline of 35.3% from the November 30th total of 79,500 shares. Based on an average daily trading volume, of 220,800 shares, the […]
October 25, 2023
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual...
October 7, 2023
Wedbush reaffirmed their outperform rating on shares of Freeline Therapeutics (NASDAQ:FRLN – Free Report) in a report issued on Wednesday, RTT News reports. They currently have a $8.00 target price on the stock, up from their previous target price of $5.00. Separately, HC Wainwright reissued a buy rating and issued a $15.00 target price on […]
August 25, 2023
CHI Advisors LLC cut its holdings in Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Free Report) by 1.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 4,729,419 shares of the company’s stock after selling 85,000 shares during the period. Freeline Therapeutics comprises approximately 0.6% of CHI Advisors […]
August 18, 2023
HC Wainwright reaffirmed their buy rating on shares of Freeline Therapeutics (NASDAQ:FRLN – Free Report) in a research report released on Thursday, Benzinga reports. The firm currently has a $15.00 target price on the stock. A number of other equities research analysts have also recently commented on FRLN. Stifel Nicolaus increased their price target on […]
August 4, 2023
HC Wainwright restated their buy rating on shares of Freeline Therapeutics (NASDAQ:FRLN – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $15.00 price objective on the stock. Several other analysts have also commented on the stock. BTIG Research reduced their price target on shares of […]
July 25, 2023
Webinar to take place on August 1, 2023, at 8:30 AM ET...
July 3, 2023
Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Free Report) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 55,400 shares, an increase of 93.7% from the May 31st total of 28,600 shares. Based on an average daily trading volume, of 111,200 shares, the days-to-cover […]
June 4, 2023
Freeline Therapeutics Holdings plc (NASDAQ:FRLN – Get Rating) – Wedbush cut their Q2 2023 earnings estimates for shares of Freeline Therapeutics in a research report issued on Tuesday, May 30th. Wedbush analyst D. Nierengarten now expects that the company will earn ($3.14) per share for the quarter, down from their prior forecast of ($2.99). The […]